Nxera Pharma Co., Ltd.

2026/10/21 10:58 Updated
Market Cap: $751.3M (¥118.9B)
Stock Price: $8.19 (¥1,296)
Exchange Rate: 1 USD = ¥158.23

Notice Regarding Review of Future RSU Grants for Executive Officers and Introduction of Performance-Linked Stock Option Plan for Executive Officers and Issuance of Stock Acquisition Rights under the Plan

Decided to introduce a performance-linked stock option / stock acquisition rights plan for executive officers. A total of 66,500 units, corresponding to up to 6,650,000 shares, are eligible, with five-tier stock price hurdles ranging from 2,200 yen to 10,000 yen. Exercise is generally locked for 3 years, with a maximum term of 10 years. The plan covers three officers: CEO, CFO, and COO. A review of RSU grant levels is also planned for early 2027.

Importance:
Page Updated: October 20, 2026
IR Disclosure Date: October 20, 2026

Key Figures

  • Total number of stock acquisition rights: 66,500 units
  • Maximum number of shares subject to the plan: 6,650,000 shares
  • Most frequent stock price hurdles: 2,200 yen–10,000 yen (5 tiers)

AI要約

Plan Overview and Purpose

This plan is a performance-linked compensation scheme for three executive officers, where stock acquisition rights vest only upon achieving specified stock price hurdles. Allocations are divided into five tranches, and each tranche requires meeting one of five stock price hurdles (minimum 2,200 yen, maximum 10,000 yen). After vesting, exercise is generally prohibited for three years, and vesting conditions require both continued service and achievement of stock price targets. The maximum number of shares to be issued is 6,650,000 shares, and the eligible persons are the CEO, CFO, and COO.

Impact and Future Actions

Potential dilution from equity-based compensation could reach up to 7.2% of total issued shares; however, dilution is mitigated by strict tranche achievement and exercise conditions, a three-year lock-up, and prohibition of additional grants. Expenses will be recognized in accordance with IFRS 2, and the impact on consolidated results for the fiscal year ending December 2026 is under review. A review of RSU grant levels is scheduled for early 2027.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Nxera Pharma Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →